Balaban N, Collins L V, Cullor J S, Hume E B, Medina-Acosta E, Vieira da Motta O, O'Callaghan R, Rossitto P V, Shirtliff M E, Serafim da Silveira L, Tarkowski A, Torres J V
Department of Medical Pathology, University of California, Davis 95616, USA.
Peptides. 2000 Sep;21(9):1301-11. doi: 10.1016/s0196-9781(00)00272-2.
Staphylococcus aureus causes many diseases including cellulitis, keratitis, osteomyelitis, septic arthritis and mastitis. The heptapeptide RIP has been shown to prevent cellulitis in mice, which was induced by S. aureus strain Smith diffuse. Here we show that RIP can also significantly reduce the overall pathology and delay the onset of disease symptoms in several other models of S. aureus infections, including: keratitis (tested in rabbits against S. aureus 8325-4), osteomyelitis (tested in rabbits against S. aureus MS), mastitis (tested in cows against S. aureus Newbould 305, AE-1, and environmental infections) and septic arthritis (tested in mice against S. aureus LS-1). These findings substantiate that RIP is not strain specific in its inhibitory activity and that RIP is an effective inhibitor of bacterial pathology at multiple body sites following diverse routes and doses of administration. These findings strongly evidence the potential value of RIP as a chemotherapeutic agent.
